NASDAQ: XLOXilio Therapeutics Inc Stock Ownership - Who owns Xilio Therapeutics?
Insider buying vs selling
Have Xilio Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Kevin M. Brennan | SVP FINANCE AND ACCOUNTING | 2025-01-02 | 1,803 | $0.98 | $1.77kSell |
| Christopher James Frankenfield | Chief Financial Officer | 2025-01-02 | 6,954 | $0.98 | $6.84kSell |
| Gilead Sciences Inc | 10% Owner | 2024-12-18 | 1,759,978 | $1.04 | $1.83MBuy |
XLO insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when XLO insiders and whales buy or sell their stock.
XLO Shareholders
What type of owners hold Xilio Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Gilead Sciences Inc | 17.58% | 9,105,451 | $6.03M | Insider |
| Gilead Sciences Inc | 17.58% | 9,105,451 | $6.03M | Institution |
| Yekaterina Chudnovsky | 13.52% | 7,000,000 | $4.63M | Insider |
| Bain Capital Life Sciences Investors LLC | 8.82% | 4,566,817 | $3.02M | Institution |
| Sv7 Impact Medicine Fund LP | 6.23% | 3,227,264 | $2.14M | Insider |
| Bain Capital Life Sciences Investors LLC | 5.42% | 2,805,413 | $1.86M | Insider |
| Atlas Venture Fund XI LP | 5.32% | 2,754,109 | $1.82M | Insider |
| James E. Flynn | 4.42% | 2,287,944 | $1.51M | Insider |
| Merck Co Inc | 2.87% | 1,483,758 | $982.25k | Institution |
| Takeda Pharmaceutical Co Ltd | 2.85% | 1,475,121 | $976.53k | Insider |
XLO vs Biotech Stocks
Xilio Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.